TESAMORELIN

Growth Hormone SecretionPrescription Available

One of the most rigorously studied peptides with genuine FDA approval and consistent results across multiple populations. The evidence base is unusually robust for a peptide therapy.

Endocrinologists and HIV specialists study it most frequently, along with researchers investigating visceral obesity, fatty liver disease, and metabolic syndrome.

FDA Status

FDA Approved

Since Nov 2010

Evidence

Strong

Studies

30 total, 20 human

Popularity

#9 most researched

What is TESAMORELIN?

Originally developed for HIV patients dealing with lipodystrophy, this synthetic growth hormone-releasing hormone analog has carved out a unique niche in body composition research. Unlike broader growth hormone therapies, tesamorelin targets visceral fat accumulation specifically, making it particularly valuable for researchers studying abdominal obesity and metabolic dysfunction. Compounding pharmacies provide access for approved medical uses, though research applications extend beyond the original HIV population.

Tesamorelin mimics the natural growth hormone-releasing hormone (GHRH) produced by the hypothalamus, binding to the same receptors in the pituitary gland to trigger endogenous growth hormone release. Rather than flooding the system with external growth hormone, it works through the body's existing regulatory pathways, which appears to create more targeted effects on fat distribution. The resulting growth hormone pulses seem particularly effective at mobilizing visceral adipose tissue—the deep abdominal fat linked to metabolic problems.

What the Research Shows

Exceptional evidence quality with 19 randomized controlled trials among 30 total studies, including the rigorous clinical trials required for FDA approval.

Across 30 human studies including 19 randomized controlled trials, tesamorelin has demonstrated FDA approval for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, with consistent evidence showing significant reductions in visceral fat, hepatic fat, and trunk-to-appendicular fat ratio while producing minimal glycemic effects in HIV populations and reducing cholesterol without altering insulin response in type 2 diabetic patients.